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Essential Role of Caveolin-3 in Adiponectin Signalsome
Formation and Adiponectin Cardioprotection
Yajing Wang, Xiaoliang Wang, Jean-François Jasmin, Wayne Bond Lau, Rong Li, Yuexin Yuan,
Wei Yi, Kurt Chuprun, Michael P. Lisanti, Walter J. Koch, Erhe Gao, Xin-Liang Ma
Objective—Adiponectin (APN) system malfunction is causatively related to increased cardiovascular morbidity/mortality
in diabetic patients. The aim of the current study was to investigate molecular mechanisms responsible for APN
transmembrane signaling and cardioprotection.
Methods and Results—Compared with wild-type mice, caveolin-3 knockout (Cav-3KO) mice exhibited modestly
increased myocardial ischemia/reperfusion injury (increased infarct size, apoptosis, and poorer cardiac function
recovery; P0.05). Although the expression level of key APN signaling molecules was normal in Cav-3KO, the
cardioprotective effects of APN observed in wild-type were either markedly reduced or completely lost in Cav-3KO.
Molecular and cellular experiments revealed that APN receptor 1 (AdipoR1) colocalized with Cav-3, forming
AdipoR1/Cav-3 complex via specific Cav-3 scaffolding domain binding motifs. AdipoR1/Cav-3 interaction was
required for APN-initiated AMP-activated protein kinase (AMPK)–dependent and AMPK-independent intracellular
cardioprotective signalings. More importantly, APPL1 and adenylate cyclase, 2 immediately downstream molecules
required for AMPK-dependent and AMPK-independent signaling, respectively, formed a protein complex with
AdipoR1 in a Cav-3 dependent fashion. Finally, pharmacological activation of both AMPK plus protein kinase A
significantly reduced myocardial infarct size and improved cardiac function in Cav-3KO animals.
Conclusion—Taken together, these results demonstrated for the first time that Cav-3 plays an essential role in APN
transmembrane signaling and APN anti-ischemic/cardioprotective actions. (Arterioscler Thromb Vasc Biol. 2012;32:
934-942.)
Key Words: cytokines  diabetes mellitus  reperfusion injury  signal transduction
Ischemic heart disease is the leading cause of death inpatients with diabetes. Hyperglycemia and hyperlipidemia
not only cause vascular injury resulting in myocardial isch-
emia but also directly adversely impact ischemic cardiomy-
ocytes, causing larger infarct size, and more severe heart
failure after myocardial ischemia.1 Defining the molecular
basis linking diabetes and ischemic heart disease may help in
identifying novel therapeutic targets that will not only reduce
myocardial infarction risk but also decrease cardiovascular
mortality in diabetic patients.
Adiponectin (APN) is an adipocytokine secreted from
adipose tissue. Clinical and experimental studies have dem-
onstrated the potency of APN as an endogenous cardiovas-
cular protective molecule. Reduced APN levels in type-2
diabetic patients not only contribute to increased vascular
injury and MI morbidity but also play a causative role in
increased cardiomyocyte death, and greater mortality in
diabetic individuals post-MI.2–5 However, knowledge of the
molecular mechanisms responsible for APN-induced cardio-
myocyte protection against MI injury remains elusive. More
importantly, although several putative APN receptors have
been proposed, transmembrane signaling mechanisms re-
sponsible for APN=s cardiomyocyte-protective effect remain
undefined.
Caveolae are small, flask-like invaginations of the plasma
membrane that create signaling microdomains, thereby pro-
viding spatial and temporal organization of cellular signaling
events. Caveolins, the structural proteins found in caveolae,
serve as scaffolds and regulators of signaling proteins.6 Many
signaling molecules compartmentalize within caveolae and
interact with the scaffolding domain of caveolins. Numerous
studies have demonstrated that caveolin scaffolding domain
binding inhibits the function of multiple caveolar proteins
involved in cell growth and proliferation.7 Thus, caveolin has
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been generally recognized as a signal inhibitor and a potent
growth suppressor. However, recent studies have suggested
that insulin signaling may be an exception, which requires the
presence of caveolin for transmembrane signaling.8 Numer-
ous studies have demonstrated that APN shares many biolog-
ical functions with insulin, including glucose uptake, lipid
oxidation, and cardiovascular protection.9,10 However, the
role of caveolin in APN transmembrane signaling, ie, func-
tioning as either an inhibitor or activator, has never been
previously investigated.
Therefore, the aims of the present study were to (1)
determine the role of caveolin-3 (Cav-3) (the predominant
form of caveolin expressed in cardiomyocytes) in the cardio-
protective actions of APN, and (2) investigate the molecular
mechanisms responsible for Cav-3 regulation of APN trans-
membrane signaling.
Materials and Methods
All experiments were performed on adult (8–10 weeks) male Cav-3
knockout (Cav-3KO) mice or male wild-type (WT) littermate con-
trols. Generation and characterization of Cav-3KO mice have been
previously described.11 The experiments were performed in adher-
ence with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Thomas
Jefferson University Committee on Animal Care.
Mice were anesthetized with 2% isoflurane, and myocardial
ischemia (MI) was produced by temporarily exteriorizing the heart
via a left thoracic incision and placing a 6-0 silk suture slipknot
around the left anterior descending coronary artery.5 Twenty minutes
after MI, animals were randomized to receive either vehicle or
globular domain of APN (2 g/g, IP).5 After 30 minutes of MI, the
slipknot was released, and the myocardium was reperfused for 3
hours or 24 hours (cardiac function and infarct size only). All assays
were performed using tissue from ischemic/reperfused area or area at
risk identified with Evens blue negative staining.
Cardiac function was determined by echocardiography (Visual-
Sonics VeVo 770) and left ventricular (LV) catheterization (Millar
1.2-Fr micromanometer) methods 24 hours after reperfusion and
before chest reopening.5 Myocardial apoptosis was determined by
caspase-3 activity and expressed as nmol of pNA/hour per mg of
protein.5 Total nitric oxide content (SIEVER 280i chemilumines-
cence NO Analyzer), superoxide production (lucigenin-enhanced
chemiluminescence), and nitrotyrosine content (ELISA) in cardiac
tissue were determined as we previously published.12–14 Sucrose
density membrane fractionation, immunoblotting, coimmunoprecipi-
tation, adult mouse cardiomyocyte culture, and confocal microscopic
analysis were all performed using standard methods from our
laboratory5 or other investigators. Detailed methods for all of the
assays described above, as well as the methods for plasmid produc-
tion and cell transfection, are provided in the online-only Data
Supplement.
All values in the text and figures are presented as meansSEM of
n independent experiments. All data (except Western blot density)
were subjected to 2-way ANOVA followed by Bonferroni correction
for post hoc test. Western blot densities were analyzed with the
Kruskal-Wallis test followed by Dunn’s post hoc test. Probabilities
of 0.05 or less were considered statistically significant.
Results
Knockout of Cav-3 Modestly Increased
Myocardial Ischemia/Reperfusion Injury but
Virtually Abolished the Cardioprotection of APN
To definitively determine the role of Cav-3 in APN-mediated
cardioprotection, the effect of APN on myocardial infarct size
was determined in Cav-3KO mice and their WT littermates.
As summarized in Figure 1A, administration of APN 10
minutes before reperfusion significantly decreased infarct
size in WT mice (P0.01). Compared with WT mice,
Cav-3KO mice exhibited moderately increased infarct size
(P0.05). Most importantly, administration of APN to Cav-
3KO mice only slightly reduced infarct size. A highly
significant difference in infarct size between APN-treated
WT mice and APN-treated Cav-3KO mice was observed
(P0.01). The loss of APN-mediated protection in Cav-3KO
mice cannot be attributed to reduced APN concentration in
these animals (P0.05),11 as treatment with a tripled dose of
APN (ie, 6 g/g body weight) remained ineffective in
reducing infarct size. Moreover, the loss of APN cardiopro-
tection in Cav-3KO mice cannot be explained by a modestly
larger infarct size observed in Cav-3KO mice, because we
have recently demonstrated that APN is highly effective in
protecting heart from myocardial ischemia/reperfusion
(MI/R) injury in APN knockout mice, an animal model in
which infarct size is even larger than that seen in Cav-3KO
mice.5 Finally, to determine whether Cav-3 is also required
for cardioprotective action of full-length APN, HEK cell-
produced full-length APN (80% in high molecular weight
format as certified by the manufacturer, BioVendor, Candler,
NC) was administered at 10 g/g (a dose that exerts compa-
rable cardioprotection in WT animal as 2 g/g globular
APN). As summarized in Figure I in the online-only Data
Supplement, the cardioprotective effect of full-length APN
observed in WT mice was virtually abolished in Cav-3KO
animals. These results demonstrated that Cav-3 is an essential
molecule in APN-mediated cardioprotection.
Apoptosis plays a critical role in MI/R injury. To determine
whether Cav-3 is also required in APN-mediated antiapop-
totic signaling, the effect of APN on MI/R-induced caspase-3
activation was determined. Compared with WT mice, MI/R-
induced caspase-3 activation was significantly increased in
Cav-3KO mice. More importantly, the antiapoptotic effect of
APN observed in WT mice was markedly, although not
completely, blocked in Cav-3KO mice (Figure 1B). The
difference in caspase-3 activity between APN-treated WT
and APN-treated Cav-3KO mice was markedly significant
(P0.01).
Echocardiography and LV catheterization were used 24
hours after reperfusion to ascertain whether the beneficial
effects of APN on cardiac function were Cav-3 dependent. As
illustrated in Figure 1C and summarized in Figure 1D, MI/R
caused greater LV dysfunction in Cav-3KO mice than WT
(P0.05). Although APN treatment significantly improved
LV function in WT mice, the same treatment failed to
improve LV function to significant extent in Cav-3KO mice
(Figure 1C and 1D). As seen with echocardiography, Cav-
3KO mice manifested significantly poorer cardiac function
by LV catheterization, as evidenced by higher LV end
diastolic pressure and lower dP/dtmax (Figure 1E and 1F).
Treatment of WT mice with APN significantly reduced LV
end diastolic pressure (P0.01) and improved dP/dtmax
(P0.01). However, the beneficial effects of APN on cardiac
function were either markedly reduced or completely lost in
Cav-3KO mice. There was a highly significant difference in
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dP/dtmax between APN-treated WT mice and APN-treated
Cav-3KO mice (Figure 1E and 1F).
APN Signaling Machinery Is Intact in
Cav-3KO Mice
The above results clearly demonstrate that Cav-3 is required
for APN-mediated cardioprotective signaling. To determine
the mechanisms responsible for the loss of APN-mediated
cardioprotection in Cav-3KO mice, we first assessed the state
of molecules requisite for physiological APN biological
signaling. No difference in cardiac expression of APN recep-
tor (AdipoR)-1, AdipoR2, APPL1 (an adaptor protein con-
taining a phosphotyrosine binding domain, a pleckstrin
homology domain, and a leucine zipper motif), or AMP-
activated protein kinase (AMPK) was observed between WT
and Cav-3KO mice (Figure I in the online-only Data Supple-
ment). These results demonstrate that the loss of APN-
mediated cardioprotection in Cav-3KO mice cannot be attrib-
Figure 1. Knockout of Cav-3 abolished APN=s infarct size sparing effect (A), markedly blunted APN=s antiapoptotic effect (B), and abol-
ished APN=s cardiac functional improvement effect as determined by LVEF (C and D) and dP/dtmax (E and F). n12 to 15/group.
*P0.05, **P0.01 vs the respective vehicle group; &P0.05, &&P0.01 vs WT mice with the same treatment in ischemic/reperfused
heart. n12 to 15/group. APN indicates adiponectin; Cav3, caveolin-3; LVEF, left ventricular ejection fraction; MI/R, myocardial isch-
emia/reperfusion; V, vehicle; WT, wild-type.
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uted to the deficiency of key membrane or intracellular APN
signaling molecules.
Colocalization and Interaction of AdipoR1 and
Cav-3 in Adult Cardiomyocytes
Previous studies have demonstrated that caveolin interacts
with many membrane receptors. Recent studies have demon-
strated that APN receptors are 7-transmembrane domain
proteins, but with structural and topologic distinction from
G-protein–coupled receptors.15 Having demonstrated that
APN=s cardioprotection is abolished in Cav-3KO mice, we
decided to test a novel hypothesis that interaction between
AdipoR1, the predominant form of APN receptor in muscular
cells, and Cav-3, the predominant form of caveolin in
muscular cells, might be requisite for proper APN transmem-
brane signaling and cardioprotection. As illustrated in Figure
2A, AdipoR1 (green fluorescence) and Cav-3 (red fluores-
cence) were both confined to the plasma membrane. The
image overlay demonstrates colocalization of AdipoR1and
Cav-3 (yellow staining). The staining was specific for Adi-
poR1 and Cav-3, because substitution of nonimmune IgG for
AdipoR1 antibody yielded only red plasma membrane stain-
ing, and substitution of Cav-3 antibody with nonimmune IgG
resulted in only AdipoR1 green staining (data not shown). To
determine whether there is an interaction between Cav-3 and
AdipoR1, cardiac lysates were immunoprecipitated with an
antibody directed against Cav-3 or a nonimmune IgG, and
AdipoR1/Cav-3 proteins in the precipitates were detected by
Western blot analysis. As illustrated in Figure 2B, neither
AdipoR1 nor Cav-3 protein was detected when samples were
immunoprecipitated with a nonimmune IgG (left lanes).
However, AdipoR1 was detected in lysates immunoprecipi-
tated with antibody against Cav-3 (right lanes). Similarly,
when cell lysates were immunoprecipitated with an antibody
against AdipoR1, Cav-3 proteins were detected by Western
blot analysis (data not shown). To confirm localization of
AdiopR1 to caveolae and AdipoR1/Cav-3 complex formation
in caveolae, a caveolae-rich detergent-resistant membrane
fraction was prepared from adult heart tissues, and AdipoR1/
Cav-3 distribution and interaction were detected by Western
blotting and coimmunoprecipitation. As shown in Figure 2C,
AdipoR1, and Cav-3 proteins were associated with the
detergent-resistant membrane fraction. Moreover, AdipoR1/
Cav-3 complex formation was clearly detected in the
detergent-resistant membrane fraction (Figure II in the
online-only Data Supplement, fractions 5 and 6) but not in
detergent-soluble fractions (Figure II in the online-only Data
Supplement, fractions 9 and 10).
AdipoR1 Binds to Cav-3 Scaffolding Domain via
Specific Cav-3 Interaction Motif
Having demonstrated that AdipoR1 colocalizes and interacts
with Cav-3, we further identified the specific domains re-
sponsible for AdipoR1/Cav-3 interaction. Previous experi-
ments have demonstrated that membrane proteins interact
with caveolin scaffolding domain via a specific caveolin-
binding motif (XXXXX or XXXXXX,  being an
aromatic residue). Sequence analysis revealed 2 potential
caveolin-binding motifs in AdipoR1 (220FVPWLYYSF228
and 325FFPGKFDIW333). To determine whether AdipoR1
binds Cav-3 via these specific motifs, vectors expressing
myc-tag full-length AdipoR1 or truncated AdipoR1 (Figure
III in the online-only Data Supplement) were cotransfected
with flag-tag full-length Cav-3 into 293T cells. Cell lysates
were immunoprecipitated with anti-myc antibody and immu-
noblotted with anti-flag antibody. As shown in Figure 2D,
Cav-3 protein was detected in cell lysates expressing full-
length AdiopR1, truncated AdipoR11-230, or truncated
AdipoR1316-375 but not in cell lysates expressing truncated
AdipoR11-215 or truncated AdipoR1337-375. These results
demonstrate that AdipoR1 interacts with Cav-3 via the
specific Cav-3 binding motif.
To further determine whether the Cav-3 scaffolding do-
main (residues 55–74) is required for AdipoR1 binding,
vectors expressing full-length Cav-3 or truncated (Figure III
in the online-only Data Supplement) Cav-3 were cotrans-
fected with myc-tag full-length AdipoR1 into 293T cells. Cell
lysates were immunoprecipitated with anti-flag antibody and
immunoblotted with anti-myc antibody. As shown in Figure
2E, AdipoR1 protein was detected in cell lysates expressing
Figure 2. AdipoR1 colocalized (A) and interacted with caveolin-3
(Cav-3) (B). C, AdipoR1 was distributed in detergent-resistant
(caveolae-rich) fractions (fractions 5 and 6), but not in detergent-
soluble fractions. D, AdipoR1/Cav-3 interaction was detected in
cells cotransfected with full-length Cav-3 plus full-length AdipoR1
(FL), truncated AdipoR11-230, or truncated AdipoR1316-375 but not
in cell lysates expressing truncated AdipoR11-215 or truncated
AdipoR1337-375. E, AdipoR1/Cav-3 interaction was detected in cells
cotransfected with full-length AdipoR1 plus full-length Cav-3 (FL) or
truncated Cav-31-74 but not in cell lysates expressing truncated
Cav-31-55 or truncated Cav-374-151. For confocal microscopic
examination, 100 cells were inspected per experiment, and cells
with typical morphology are presented. For Western and coimmu-
noprecipitation, at least 6 samples from different tissue/cell culture
dishes were examined, and typical blots are presented. IB indi-
cates immunoblotting; IP, immunoprecipitation.
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full-length Cav-3 or truncated Cav-31-74 but not in cell lysates
expressing truncated Cav-31-55 or truncated Cav-374-151.
These results demonstrate that AdipoR1 specifically binds to
the Cav-3 scaffolding domain.
Cav-3 Is Required for Both AMPK-Dependent and
AMPK-Independent APN Cardioprotection
We and others have previously demonstrated that APN
protects cardiomyocytes from ischemia/reperfusion injury via
AMPK-dependent metabolic regulation, as well as AMPK-
independent antioxidation/antinitration.16 To further deter-
mine whether AdipoR1/Cav-3 interaction is required for
AMPK-dependent or AMPK-independent intracellular car-
dioprotective signaling, the effect of APN on AMPK phos-
phorylation and nitrotyrosine content (an index for APN=s
AMPK-independent antioxidative/antinitrative properties17)
were determined. As shown in Figure 3A and 3B, AMPK and
acetyl-coenzyme A carboxylase phosphorylation was signif-
icantly increased after MI/R, and APN administration further
augmented AMPK and acetyl-coenzyme A carboxylase phos-
phorylation in WT mice. Basal levels of AMPK phosphory-
lation and MI/R-induced AMPK phosphorylation were both
slightly reduced (not statistically significant) in Cav-3KO
mice. Most importantly, administration of APN failed to
induce AMPK and acetyl-coenzyme A carboxylase phos-
phorylation in these mice (Figure 3A), indicating that Cav-3
is required for APN-induced AMPK activation.
Treatment of WT mice with APN significantly reduced
nitrotyrosine content in the ischemic/reperfused heart (Figure
3C). Basal nitrotyrosine content was unaltered, but ischemia/
reperfusion-induced nitrotyrosine formation was significantly
increased in Cav-3KO mice. Treatment of Cav-3KO mice
with APN failed to reduce nitrotyrosine content in the
ischemic/reperfused heart. To further determine the arm of
peroxynitrite overproduction (ie, overproduction of NO or
superoxide) specifically inhibited by APN in a Cav-3 depen-
dent fashion, NO/superoxide production and inducible nitric
oxide synthase/phagocyte NADPH oxidase-2 (NOX)-2 (the
prototypical and predominant form of NADPH oxidase in
adult cardiomyocytes18) expressions were determined. In WT
mice, APN significantly reduced ischemia/reperfusion-
induced NO/superoxide production (Figure 4A and 4B) and
inhibited inducible nitric oxide synthase/NOX-2 expression
(Figure 4C and 4D). Knockout of Cav-3 further aggravated
ischemia/reperfusion-induced NO/superoxide production
(Figure 4A and 4B), and elevated NOX-2 expression (Figure
4D). Ischemia/reperfusion induced inducible nitric oxide
synthase expression was slightly increased in the Cav-3KO
heart (Figure 4C). In Cav-3KO mice, the inhibitory effect of
APN on NO/superoxide production and NOX-2 overexpres-
sion was completely abolished, and the inhibitory effect of
APN on inducible nitric oxide synthase expression was
significantly blunted (Figure 4). Finally, congruent with
previous reports, whereas basal endothelial nitric oxide syn-
thase expression was unchanged, endothelial nitric oxide
synthase phosphorylation was increased in Cav-3KO heart
(Figure IV in the online-only Data Supplement). However,
APN-induced endothelial nitric oxide synthase phosphoryla-
tion was abolished in Cav-3KO heart.
AdipoR1 Interacts With APPL1 and Adenylate
Cyclase in a Largely Cav3-Dependent Fashion
Recent studies suggest that APPL1 and adenylate cyclase
(AC) are the most upstream signaling molecules in APN-
induced AMPK activation and APN=s antioxidative signaling,
respectively.16 Having demonstrated that Cav-3 is required
for both AMPK activation and antioxidative signaling of
APN, we investigated the relationships between AdipoR1,
Cav-3, APPL1, and AC to explore the potential mechanism
responsible for Cav-3-depedent APN transmembrane signal-
ing. First, cardiac lysates were immunoprecipitated with an
Figure 3. Knockout of Cav-3 abolished APN=s AMPK (A) and
ACC (B) activation and reduced its antinitrative effect (C). n12
to 15/group. **P0.01 vs the respective vehicle group;
&P0.05, &&P0.01 vs wild-type (WT) mice with the same
treatment. ACC indicates acetyl-coenzyme A carboxylase;
AMPK, AMP-activated protein kinase; APN, adiponectin; Cav3,
caveolin-3; MI/R, myocardial ischemia/reperfusion; pACC,
phospho-acetyl-coenzyme A carboxylase; WT, wild-type.
938 Arterioscler Thromb Vasc Biol April 2012
 at Thomas Jefferson Universi on July 31, 2012http://atvb.ahajournals.org/Downloaded from 
antibody against Cav-3, and immunoblotted with an antibody
against APPL1 or AC. As illustrated in Figure 5A, Cav-3
interacts with these 2 proteins to form a protein complex.
Second, cardiac lysates were immunoprecipitated with an
antibody against AdipoR1 and immunoblotted with an anti-
body against APPL1 or AC. Interestingly, both AdipoR1/
APPL1 and AdipoR1/AC complex formation were also de-
tected (Figure 5B). Finally, and most importantly, AdipoR1/
APPL1 and AdipoR1/AC interactions were markedly reduced
in Cav-3KO cardiac tissue (Figure 5B, demonstrating 80%
reduction in 5 repeated experiments).
Cotreatment With an AMPK Activator and cAMP
Mimic Significantly Reduced MI/R Injury in
Cav-3KO Mice
The aforementioned results strongly suggest that via interac-
tion with both AdipoR1 and its immediately downstream
signaling molecules, Cav-3 plays an essential role in APN
signaling complex formation. To obtain further evidence
supporting this novel hypothesis, additional experiments were
performed. WT littermates or Cav-3KO mice were subjected
to MI/R as described above and treated with either vehicle or
AICAR (an AMPK activator, 300 g/g, IP) plus N(6),2=-O-
dibutyryladenosine 3=:5= cyclic monophosphate (a cAMP
mimic, 25 g/g, IP). Dosages of AICAR and N(6),2=-O-
dibutyryladenosine 3=:5= cyclic monophosphate were selected
from previous publications, and confirmed in a pilot experi-
ment demonstrating that treatment with these 2 compounds in
Cav-3KO mice resulted in AMPK and protein kinase A
activation comparable to that seen in WT mice treated with
APN (data not shown). As summarized in Figure 5C and 5D,
although MI/R injury N(6),2=-O-dibutyryladenosine 3=:5=
cyclic monophosphate cotreatment remained highly effective
Figure 4. Knockout of Cav-3 abolished APN=s antinitrative (determined by total NO production) (A) and antioxidative (determined by
superoxide production [B] and phagocyte NADPH oxidase-2 (NOX) expression [D]) and markedly blunted APN=s anti-iNOS effect (C) in
ischemic/reperfused heart determined 3 hours after reperfusion. n12 to 15/group. *P0.05, **P0.01 vs the respective vehicle group;
&P0.05, &&P0.01 vs wild-type (WT) mice with the same treatment. APN indicates adiponectin; Cav3, caveolin-3; iNOS, inducible
nitric oxide synthase; MI/R, myocardial ischemia/reperfusion; WT, wild-type.
Wang et al Caveolin and Adiponectin Signaling 939
 at Thomas Jefferson Universi on July 31, 2012http://atvb.ahajournals.org/Downloaded from 
in reducing infarct size and improving cardiac function in
Cav-3KO mice. This result provided additional evidence that
the loss of cardioprotection of APN in Cav3-KO mice is not
the result of more severe MI/R injury in these animals.
T-Cadherin Localizes in Caveolae-Rich Membrane
Fraction of Cardiomyocytes but Does Not Interact
With AdipoR1 or Cav-3
A recent study demonstrated that T-cadherin is critical for
binding and protective functions of high molecular weight
APN in cardiac myocytes.19 To determine whether
T-cadherin expression is changed in Cav-3KO mice and
whether T-cadherin may interact with AdipoR1/Cav-3 com-
plex, an additional experiment was performed. Interestingly,
T-cadherin is distributed in detergent-insoluble, caveolae-rich
membrane fraction (Figure 6A, top). However, T-cadherin
expression was not changed in Cav-3KO heart (Figure 6A,
second panel, left half). No interaction between T-cadherin
and AdipoR1 or Cav-3 was detected (Figure 6A, second
panel, right half).
Discussion
APN regulates cellular function via binding and activation of
APN receptors (AdipoR), including AdipoR1 and AdipoR2.15
In addition to these 2 receptors, cell surface calreticulin/CD91
Figure 5. A, Cav-3 interacts with APPL1 (left) and AC (right) to
form protein complex. B, AdipoR1/APPL1 and AdipoR1/AC
complex formation was detected in tissue samples from wild-
type (WT). These interactions were markedly reduced in Cav-3
knockout (Cav-3KO) cardiac tissue (80% reduction in 5
repeated experiments). Administration of AICAR (an AMP-
activated protein kinase [AMPK] activator) plus db-cAMP (a
cAMP mimic) significantly reduced infarct size (C) and improved
cardiac function (D) in Cav-3KO mice. AAR indicates area at
risk; AC, adenylate cyclase; Cav-3, caveolin-3; Cav-3KO,
caveolin-3 knockout; IB, immunoblotting; IP, immunoprecipita-
tion; MI/R, myocardial ischemia/reperfusion; Inf, infarct;
dbcAMP, N(6),2=-O-dibutyryladenosine 3=:5= cyclic monophos-
phate, WT, wild-type.
Figure 6. A, Comparison of T-cadherin expression in wild-type
(WT) and caveolin-3 (Cav-3) knockout (Cav-3KO) heart, and
determination of T-cadherin distribution and its interaction with
AdipoR1 or Cav-3. B, Schematic illustration revealing the role of
Cav-3 in adiponectin (APN) signalsome formation and APN car-
dioprotective signaling. Solid lines: established signaling path-
ways; dashed lines: pathways requiring additional investigation.
Blue question mark indicates other intracellular APN signaling
molecules that may also be “tethered” by Cav-3. AC indicates
adenylate cyclase; APN, adiponectin; Cav-3, caveolin-3; IB,
immunoblotting; IP, immunoprecipitation; Ir, irrelevant; PKA,
protein kinase A; WT, wild-type.
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coreceptor has been shown to be the molecule responsible for
COX-2 activation by APN in endothelial cells.20 Moreover,
T-cadherin has been proposed to be a receptor for hexameric
and high-molecular-weight forms of APN.21 However,
T-cadherin lacks an intracellular domain and is mostly likely
important in tethering high molecular weight APN isoforms
on the cell surface, thus allowing their interaction with other
receptors.19 The intracellular signaling of APN has been
extensively investigated in recent years. At least 3 pathways,
including the AMPK/acetyl-coenzyme A carboxylase signal-
ing axis,22 AMPK/endothelial nitric oxide synthase axis,23,24
and AC/cAMP/protein kinase A signaling axis16,17 have been
reported. However, how the APN signal is transduced from
its receptor(s) to intracellular effectors remains largely un-
known. APPL1 is the only intracellular signaling molecule
identified thus far with ability to shuttle signaling from
AdipoR1 to intracellular effectors.10,25 However, questions
remain incompletely answered. Although the phosphoty-
rosine binding domain within APPL1 is absolutely required
for APPL1/AdipoR1 interaction, no phosphorylated tyrosine
residue is identified on AdipoR1 either before or after APN
receptor binding. Additionally, only 1-way translocation of
APPL1 (ie, from membrane to cytosol but not reversely) has
been observed after APN/receptor binding, suggesting that
those APPL1 proteins already present in close proximity to
AdipoR1 are the molecules responsible for APN signaling
propagation from membrane to intracellular effectors.
The most important finding of the present study is that Cav-3
interacts with AdipoR1, as well as APPL1 (the most important
molecule in APN=s AMPK-dependent signaling) and AC (the
most important molecule in APN=s AMPK-independent signal-
ing), forming a signaling complex (signalsome) within caveolae.
By interacting with AdipoR1 and key intracellular APN signal-
ing molecules, Cav-3 corrals such downstream molecules in
close proximity with AdipoR1, thus enabling proper transmem-
brane signaling and cardioprotection (Figure 6B). Functionally,
this AdipoR1/Cav-3 interaction is similar to that of the insulin
receptor/caveolin interaction.11,26–28 However, a difference
exists. In Cav-1 knockout adipocytes, insulin receptor mRNA
levels are not changed, but insulin receptor protein content is
markedly decreased, suggesting that Cav-1 stabilizes insulin
receptor and inhibits its degradation.29 However, our present
experiments yielded no significant change in AdipoR1/2
expression in Cav-3KO cardiomyocytes at either the mRNA
level or the protein level, suggesting the existence of more
complex mechanisms responsible for Cav-3 regulation of
AdipoR1 signaling.
Although both Cav-1KO and Cav-3KO mice manifest
reduced insulin response, only Cav-3KO mice exhibit typical
type-2 diabetic changes, including increased adiposity, de-
creased glucose uptake, reduced skeletal muscle glucose
metabolic flux, and increased plasma leptin levels.11 Impor-
tantly, older Cav-3-null mice develop pathological cardiac
phenotypes, including cardiac hypertrophy and heightened
ERK1/2 activation. However, Cav-3KO mice at age 2 months
(as in the current study) do not exhibit any myopathic
changes.11 Additionally, several recent studies have demon-
strated that Cav-3 is positively involved in post-MI cardio-
protection.30–32 Moreover, although increased MI/R injury
has been reported in both Cav-1KO and Cav-3KO mice in
vivo, our most recent preliminary data obtained in cultured
cardiomyocytes demonstrate that APN=s transmembrane sig-
naling is impaired in Cav-3, but not Cav-1, knockdown
cardiomyocytes. In contrast, Cav-1 knockdown in endothelial
cells significantly blocks APN transmembrane signaling.
Together, these results suggest that lack of Cav-1, an endo-
thelial cell caveolin subtype, may increase MI/R injury
indirectly by impairing blood flow restoration after reperfu-
sion. In contrast, lack of Cav-3, a muscle-cell specific
caveolin subtype, impairs APN transmembrane signaling in
cardiomyocytes, directly augmenting MI/R injury.
It should be indicated that Cav-3KO markedly, but not
completely, abolished all biological functions of APN, in-
cluding a small portion of antiapoptotic effect (Figure 1B)
and AMPK activating effect (Figure 3C). A previous study
has demonstrated that AdipoR1 interacts with APPL1 and
activates AMPK.25 As shown in Figure 5B, AdipoR1/APPL1
interaction is markedly reduced but not completely lost in
Cav-3KO cardiomyocytes. The remaining (approximately
20%) direct AdipoR1/APPL1 could be responsible for the
small portion of AMPK activation by APN in Cav-3KO mice.
In addition, although AdipoR1 is the predominant APN
receptor expressed in cardiomyocytes, low levels of AdipoR2
are expressed in cardiomyocytes. Sequence analysis revealed
that AdipoR2 contains 1 potential caveolin-binding motif that
is located in its transmembrane domain. No significant
AdipoR2/Cav-3 interaction was detected in our pilot experi-
ment. A small portion of biological function of APN remain-
ing in Cav-3KO mice could also be partially attributed to
AdipoR2 activation and signaling. As systemic APN mal-
function has been identified as a major risk factor for
increased cardiovascular morbidity and mortality in type-2
diabetics, detailed elucidation of the signaling cascade medi-
ated by the AdipoR1/Cav-3 interaction will not only gain
comprehension of the APN signaling pathway and its regu-
lation, but also provide valuable information on the design of
new pharmacological interventions for clinically important
diseases, such as obesity and type-2 diabetes.
While this article was in the final stages of preparation, an
excellent study was published reporting that APN activates
ceramidase in receptor-dependent fashion, initiating the
pleiotropic actions of APN.33 Our most recent experimental
results demonstrate that although ceramidase is not a compo-
nent of the Cav-3 centered APN signalsome during resting
conditions, Cav-3 plays an essential role in APN-induced
ceramidase recruitment and activation. Experiments identify-
ing the role of Cav-3 in APN-initiated ceramidase recruit-
ment/activation, and the involved detailed molecular mecha-
nisms, are currently in progress.
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Materials and Methods: 
All experiments were performed on adult male Cav-3 knockout mice (Cav-3KO) or male 
wild type littermate controls (WT). The experiments were performed in adherence with the 
National Institutes of Health Guidelines on the use of Laboratory Animals and were approved by 
the Thomas Jefferson University Committee on Animal Care. The authors had full access to and 
take full responsibility for the integrity of the data. All authors have read and agree to the 
manuscript as written. 
Myocardial ischemia/reperfusion protocols: Mice were anesthetized with 2% isoflurane (total 
exposure time <5 minutes), and myocardial ischemia (MI) was produced by temporarily 
exteriorizing the heart (<1 minute) via a left thoracic incision and placing a 6-0 silk suture 
slipknot around the left anterior descending coronary artery
1
. Twenty minutes after MI, animals 
were randomized to receive either vehicle or globular domain of adiponectin (gAPN, 2 µg/g, ip)
1
. 
After 30 minutes of MI, the slipknot was released, and the myocardium was reperfused for 3 
hours or 24 hours (cardiac function and infarct size only). All assays were performed using the 
tissue from ischemic/reperfused area or area-at-risk (AAR) identified with Evens blue negative 
staining as described below.   
Determination of Cardiac Function: 24 hours after reperfusion, cardiac function was determined 
by echocardiography (VisualSonics VeVo 770 imaging system) as well as left ventricular (LV) 
catheterization methods before the chest was reopened 
1, 2
. For echocardiography, mice were 
anesthetized with a 1.5% isoflurane and two-dimensional echocardiographic views of the mid-
ventricular short axis were obtained at the level of the papillary muscle tips below the mitral 
valve (Vevo 770, VisualSonic, Toronto, Canada). LV fractional shortening (LVFS) and LV 
ejection fraction (LVEF) were calculated. For hemodynamic measurements, the right common 
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carotid artery of mice was cannulated with 1.2 French micro-manometer (Millar Instruments, 
Houston, TX). LV pressure, LV end-diastolic pressure (LVEDP), maximal and minimum values 
of the instantaneous first derivative of LV pressure (±dP/dtmax), and heart rate (HR) were 
measured by this catheter advanced into the LV cavity, and data was recorded and analyzed on a 
PowerLab System (AD Instruments Pty Ltd., Mountain View, CA).  
Determination of Myocardial Infarct Size: At the end of the 24-hour reperfusion period, the 
ligature around the coronary artery was retied and 0.5 ml of 2% Evans blue dye was injected 
into the left ventricular cavity. The dye was circulated and uniformly distributed except in that 
portion of the heart previously perfused by the occluded coronary artery (area-at-risk, AAR). 
The heart was excised, frozen in -20
o
 C, and sliced into 1 mm thick sections perpendicular to 
the long axis of the heart. Slices were incubated individually using a 24-well culture plate in 
1% TTC in phosphate buffer at pH 7.4 at 37 C for 10 minutes, and photographed with a 
digital camera. The Evan’s blue stained area (area-not-at-risk, ANAR), the TTC stained area 
(red staining, ischemic but viable tissue), and the TTC stained negative area (infarct 
myocardium) were digitally measured using an IP Lab Imagine Analysis Software (Version 
3.6, Scanalytics, Fairfax, VA) with a custom-made script (Bio Vision Technologies, North 
Exton, PA). The myocardial infarct size was expressed as a percentage of infarct area over 
AAR. 
Measurement of caspase-3 activity: Apoptotic cell death was determined by caspase-3 activation 
as described in our previous study
2
. Briefly, 3 hours after reperfusion, heart was removed and 
cardiac tissue from AAR was homogenized
 
utilizing caspase lysis buffers (50mM HEPES PH 7.4, 
0.1% Chaps, 5mM DTT, 0.1 mM EDTA, 0.1% Triton-X100). To each well of a 96-well plate, 
supernatant containing 200 µg of protein was
 
loaded
 
and incubated with 25 µg Ac-DEVD-pNA at 
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37° C for 1.5 hours. pNA was cleaved from DEVD by activated caspase-3, and the free pNA was 
quantified using a SpectraMax-Plus microplate spectrophotometer (Molecular Devices, 
Sunnyvale, CA) at 405 nm.
 
Caspase-3 activity was expressed as nmol pNA/h/mg protein. 
Determination of Total NOx Content in Cardiac Tissue: Cardiac tissue samples from AAR were
 
rinsed, homogenized in deionized water (1:10, wt.vol
-1
), and centrifuged
 
at 14,000 x g for 10 
minutes. The tissue NO and its in vivo metabolic products (NO2 and NO3) in
 
the supernatant, 
collectively known as NOx, were determined using a chemiluminescence NO detector (SIEVER 
280i NO Analyzer) as described in our previous study 
3
. 
Quantification of Superoxide Production: Superoxide production in ischemic/reperfused heart 
tissue was measured by lucigenin-enhanced chemiluminescence as  previously described 
4
. 
Superoxide production was expressed as relative light units (RLU) per second per mg heart 
weight (RLU.mg
-1
.s
-1
). 
Quantitation of Tissue Nitrotyrosine Content: Nitrotyrosine content in the ischemic/reperfused 
cardiac tissue, a footprint of in vivo peroxynitrite formation and a reliable index for nitrative 
stress 
5, 6
, was determined using an ELISA method described in our previous publication 
7
. The 
results were presented as pmol of nitrotyrosine/mg protein. 
Immunoblotting: Protein from tissue homogenate was separated on SDS-PAGE gels, transferred 
to nitrocellulose membranes, and Western blotted with monoclonal antibody against iNOS, 
NOX-2, AMPK, pAMPK, ACC and pACC. Nitrocellulose membranes were then incubated with
 
HRP-conjugated anti-mouse IgG antibody (1:2000, Cell Signaling) for 1 hour and the blot was 
developed with a Supersignal chemiluminescence detection kit (Pierce). The immunoblotting 
was visualized with a Kodak Image Station 400 and the blot densities were analyzed with Kodak 
1D software.   
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Sucrose density membrane fractionation: Whole hearts were homogenized in Triton X-100 with 
a tissue grinder followed by sonication. The resulting cell lysates were mixed with equal 
amounts of 80% sucrose in MBS, yielding a 40% sucrose concentration. Lysates containing the 
40% sucrose were loaded at the bottom of an ultracentrifuge tube, and overlaid with 4 ml each of 
35% and 5% sucrose in MBS. The gradient was centrifuged at 175,000 g with a Beckman 
SW41Ti rotor (Beckman Instruments, Fullerton, CA, USA) for 24 hours at 4°C. The resulting 
gradient fractions were analyzed by collecting twelve 1-ml fractions from the bottom of the 
gradient. Fractions 4-6 were buoyant membrane fractions (BFs) enriched in caveolae. Fractions 
9-12 were defined as non-buoyant fractions (non-BFs). The fractions were subjected to co-
immunoprecipitation or Western blot analysis as described in detail below. 
Adult mouse cardiomyocyte culture and confocal microscopic analysis: Adult mouse 
cardiomyocytes were isolated as previously described
1
. Cells were washed and fixed with 4% 
paraformaldehyde/PBS. The samples were pretreated with 10% fetal bovine serum in phosphate 
buffered saline for 30 minutes. After PBS rinsing, rabbit anti-mouse Cav-3 or goat anti-mouse 
APN receptor 1 (AdipoR1) antibody (1:200) in the same blocking solution were added to the 
sample and incubated for 1 hour. Nonimmune rabbit IgG and goat IgG were included as controls. 
Following five 5-minute washes with blocking solutions, tetramethyl rhodamine (TRITC)-
conjugated chicken anti-rabbit IgG and Cy5-conjugated donkey anti-goat IgG (Abcam, 
Cambridge, MA.1:200) were added, and incubated for 30 minutes. After washing with 
phosphate-buffered saline, coverslips were mounted using an anti-fade solution (KPL, 
Gaithersburg, MD). Samples were examined with a FV1000 confocal microscope (Olympus, 
Tokyo, Japan), and images were processed with the Fluoview software (Olympus).  More than 
100 cells were inspected per experiment, and cells with typical morphology are presented.   
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Plasmid production, cell transfection and co-immunoprecipitation: Full-length AdipoR1 
(residues 1–375, AdipoR1-F) and truncated AdipoR1 (AdipoR1-T), including AdipoR1-T1-230, 
AdipoR1-T
1-215
, AdipoR1-T
316-375
, AdipoR1-T
336-375
 were generated by PCR using the wild type 
mouse AdipoR1 cDNA (gift from Dr. Lily Dong, Department of Pharmacology, University of 
Texas Health Science Center, San Antonio, TX) as a template, and cloned into pcDNA3.1 with 
myc-tag. Full length Cav-3 (residue 1-151, Cav-3F) and truncated Cav-3 (Cav-3T), including 
Cav-3T
1-74
, Cav-3T
1-54
, Cav-3T
54-74
, and Cav-3T
74-151 
were generated by PCR using the wild-type 
mouse Cav-3 cDNA as a template, and cloned into the p3XFLAG. Human embryonic kidney 
293T cells were grown to 90% confluence in 6-well dishes, and transfected with plasmids 
encoding AdiopR1-F,  AdipoR1-T, Cav-3F, Cav-3T (2 g DNA), or empty vectors (p3XFLAG or  
pcDNA3.1) by Lipofectamine 2000 Reagent per manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). Cells were incubated with lipid–DNA complexes in serum-free DMEM for 8 
hours. Following transfection, cells were washed twice with PBS, and cultured in medium 
containing 10% serum till confluence. Cells were scraped into 1 ml of ice cold RIPA lysis buffer 
(1XTBS, 1% Nonidet p-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide, 1mM 
Na3VO4, 0.5mM EDTA, supplemented with protease inhibitor cocktail). After sonication on ice, 
debris was removed by centrifugation at 12,000 g for 10 minutes. Lysates were pre-cleared by 
incubation with 30µl of a 1:1 slurry of Protein G-Sepharose for 30 minutes at 4°C on a rotating 
wheel. The bead pellet was discarded, and the supernatant was used for immunoprecipitation. 
4µg of anti-flag IgG or Anti-myc IgG  (Sigma) was added to the lysates and incubated overnight 
at 4°C on a rotating wheel. Irrelative anti-mouse IgG served as negative control. Fresh Protein G-
Sepharose (30µl) was then added, and samples were incubated for 4 hours at 4°C. Immune 
complexes were collected by centrifugation, washed three times sequentially with each of the 
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following solutions: RIPA buffer, buffer A (50mM pH7.5 Tris, 500mM NaCl, 1mM EDTA and 
0.2% Triton X-100) and buffer B (10mM pH7.5 Tris and 0.2% Triton X-100).  Complexes were 
then disrupted by boiling in elusion buffer (Pierce).   
Statistical analysis: All values in the text and figures are presented as means±SEM of n 
independent experiments. All data (except Western blot density) were subjected to two-way 
ANOVA followed by Bonferoni correction for post-hoc test. Western blot densities were 
analyzed with the Kruskal-Wallis test followed by Dunn’s post-hoc test. Probabilities of 0.05 or 
less were considered to be statistically significant. 
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Figure I. Knockout of Cav-3 blocked cardioprotective effects of full length APN (10 µg/g).  
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Figure II. Knockout of Cav-3 had no significant effect on key APN signaling molecules 
including AdipoR1 (A), AdipoR2 (B), APPL1 (C) and AMPK (D). Top insert: typical Western 
blots; Bar graphs: summary data from at least 6 heart/group.  
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Figure III. AdipoR1/Cav-3 complex was detected  
in fractions 5 and 6,  but no in fractions 9 and 10.  
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Figure IV. A diagram depicts the truncation mutations of AdipoR1 (a) and Cav-3 (b).  
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Figure V. Treatment with APN significantly 
increased eNOS phosphorylation in WT mice 
(lane 3 vs. lane 1). Basal level of eNOS 
phosphorylation was increased in Cav-3KO 
mice (lane 4 vs. lane 1). However, treatment 
with APN failed to increase eNOS 
phosphorylation in Cav-3KO mice (lane 6 vs. 
lane 4).   
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